CRISPR THERAPEUTICS AG Contract Liability (Deferred Revenue)
CRISPR THERAPEUTICS AG (CRSP) had Contract Liability (Deferred Revenue) of $15.19 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-03
- 2026-06-30: Contract with Customer, Liability, Current $15.19M.
- 2026-03-31: Contract with Customer, Liability, Current $15.34M.
- 2025-12-31: Contract with Customer, Liability, Current $15.77M.
- 2025-09-30: Contract with Customer, Liability, Current $1.29M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $15.19M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $15.34M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $15.77M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $1.29M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $2.13M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $3.02M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $3.85M 10-K · filed 2026-02-12 |
| 2024-09-30 | $4.48M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $4.76M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $4.07M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $4.11M 10-K · filed 2025-02-11 |
| 2023-09-30 | $3.50M 10-Q · filed 2023-11-06 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-21 |
| 2021-12-31 | $1.01M 10-K · filed 2023-02-21 |
| 2021-09-30 | $1.56M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $2.07M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $1.80M 10-Q · filed 2021-04-27 |
| 2020-12-31 | $2.34M 10-K · filed 2022-02-15 |
| 2020-09-30 | $610.00K 10-Q · filed 2020-10-28 |
| 2020-06-30 | $759.00K 10-Q · filed 2020-07-27 |
| 2020-03-31 | $803.00K 10-Q · filed 2020-04-28 |
| 2019-12-31 | $960.00K 10-K · filed 2021-02-16 |
| 2019-09-30 | $47.73M 10-Q · filed 2019-10-28 |
| 2018-12-31 | $102.00K 10-K · filed 2020-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |